Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRMD

CorMedix Inc

Dec 05 • 04:00PM ET

10.56

-0.08 -0.75 %

Healthcare • Biotechnology • USA • NASD

Peers: BCRX ADMA ANIP CTSO RMTI AMRX CRVS CLSD XTNT NAII

| Held by: VTI IWM VXF IWO IBB VTWO XPH SCHA SFLO IWC

Scroll to Statements

Index	RUT	P/E	5.14	EPS (ttm)	2.05	Insider Own	11.97%	Shs Outstand	78.35M	Perf Week	7.65%
Market Cap	832.01M	Forward P/E	4.16	EPS next Y	2.54	Insider Trans	-2.50%	Shs Float	69.35M	Perf Month	-5.38%
Enterprise Value	780.68M	PEG	-	EPS next Q	0.84	Inst Own	56.57%	Short Float	25.16%	Perf Quarter	-17.18%
Income	162.50M	P/S	3.88	EPS this Y	1006.19%	Inst Trans	12.58%	Short Ratio	6.16	Perf Half Y	-24.46%
Sales	214.30M	P/B	2.21	EPS next Y	-6.52%	ROA	39.23%	Short Interest	17.45M	Perf YTD	30.37%
Book/sh	4.78	P/C	14.93	EPS next 5Y	-	ROE	75.08%	52W High	17.43 -39.41%	Perf Year	7.21%
Cash/sh	0.71	P/FCF	11.18	EPS past 3/5Y	25.91% 29.80%	ROIC	43.09%	52W Low	5.60 88.57%	Perf 3Y	153.85%
Dividend Est.	-	EV/EBITDA	7.21	Sales past 3/5Y	510.62% 173.65%	Gross Margin	92.61%	Volatility	4.45% 5.90%	Perf 5Y	17.33%
Dividend TTM	-	EV/Sales	3.64	EPS Y/Y TTM	381.63%	Oper. Margin	48.51%	ATR (14)	0.57	Perf 10Y	-15.18%
Dividend Ex-Date	-	Quick Ratio	1.73	Sales Y/Y TTM	1647.67%	Profit Margin	75.83%	RSI (14)	51.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.94	EPS Q/Q	2767.80%	SMA20	2.45%	Beta	1.37	Target Price	19.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	810.22%	SMA50	-2.34%	Rel Volume	0.57	Prev Close	10.64
Employees	65	LT Debt/Eq	0.01	Earnings	Nov 12 BMO	SMA200	-5.17%	Avg Volume	2.83M	Price	10.56
IPO	May 13, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	98.64% 21.25%	Trades		Volume	1,609,351	Change	-0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy	$14
Jun-30-25	Initiated	H.C. Wainwright	Buy	$20
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Mar-07-25	Initiated	Leerink Partners	Outperform	$18
Jan-13-25	Initiated	D. Boral Capital	Buy	$15
Aug-26-24	Initiated	Rodman & Renshaw	Buy	$13
Aug-10-23	Initiated	RBC Capital Mkts	Outperform	$6
Feb-17-21	Initiated	Needham	Buy	$31
Sep-29-20	Initiated	JMP Securities	Mkt Outperform	$22
Sep-21-20	Initiated	Truist	Buy	$20
Dec-18-19	Initiated	B. Riley FBR	Buy	$48
Mar-26-19	Reiterated	H.C. Wainwright	Buy	$3 → $15
Dec-06-18	Initiated	ROTH Capital	Buy	$6
Sep-25-17	Reiterated	H.C. Wainwright	Buy	$3 → $4
Aug-10-17	Reiterated	Rodman & Renshaw	Buy	$5 → $3
May-05-17	Reiterated	Rodman & Renshaw	Buy	$6 → $5
Nov-11-16	Reiterated	FBR & Co.	Outperform	$6 → $4
Mar-17-16	Reiterated	FBR Capital	Outperform	$7 → $6
Mar-03-16	Initiated	FBR Capital	Outperform	$7
Nov-16-15	Reiterated	ROTH Capital	Neutral	$2.75 → $2.50

Show Previous Ratings

Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
09:23AM	Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead? (Zacks)
Dec-04-25 10:29AM	BMY Gains on News of Continuation of Alzheimer's Disease Study (Zacks)
09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
12:41PM	Loading…
Dec-03-25 12:41PM	Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case (Zacks) +5.52%
10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
Dec-02-25 02:21PM	REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD (Zacks)
02:20PM	BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business (Zacks)
10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-25-25 10:45AM	SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria (Zacks)
Nov-24-25 01:53PM	BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study (Zacks)
10:50AM	Loading…
10:50AM	FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer (Zacks)
Nov-20-25 08:00PM	Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... (GuruFocus.com)
12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
09:14AM	ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal (Zacks)
Nov-19-25 10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
Nov-18-25 12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
10:36AM	Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal (Zacks)
06:16AM	Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 (Insider Monkey)
05:07AM	H.C. Wainwright Raises the PT on ?CorMedix Inc. (CRMD), Keeps a Buy (Insider Monkey)
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks) -11.21%
Nov-12-25 04:05PM	Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
07:38AM	CorMedix: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance (GlobeNewswire)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
09:00AM	CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates (Zacks)
09:55AM	Loading…
Nov-10-25 09:55AM	Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know (Zacks)
Nov-07-25 01:45PM	IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y (Zacks)
11:20AM	Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales (Zacks)
Nov-06-25 01:59PM	Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
10:50AM	JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
Nov-05-25 02:18PM	Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:11AM	Bet on 5 Top-Ranked Stocks With Rising P/E (Zacks)
Nov-04-25 12:00PM	All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy (Zacks)
07:22AM	New Strong Buy Stocks for November 4th (Zacks)
Oct-31-25 08:30AM	CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 (GlobeNewswire)
Oct-30-25 02:05PM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
12:41PM	MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down (Zacks)
12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
08:52AM	4 High-Earnings Yield Value Picks Ahead of Potential Fed Rate Cut (Zacks)
Oct-28-25 10:40AM	Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report? (Zacks)
Oct-23-25 08:30AM	CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath (GlobeNewswire)
Oct-22-25 04:05PM	Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
10:18AM	SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study (Zacks)
Oct-21-25 12:20PM	Earnings Estimates Rising for CorMedix (CRMD): Will It Gain? (Zacks)
09:55AM	Wall Street Analysts See a 68.59% Upside in CorMedix (CRMD): Can the Stock Really Move This High? (Zacks)
09:15AM	CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Talphera Announces the Appointment of Joe Todisco to Board of Directors (PR Newswire)
Oct-20-25 10:10AM	How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results? (Zacks) +19.45%
07:30AM	CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance (GlobeNewswire)
Oct-15-25 10:05AM	Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX (Zacks)
Oct-14-25 10:38AM	CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip? (Zacks)
08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
Oct-07-25 10:32AM	Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? (Zacks)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)
Oct-03-25 08:44AM	ILMN Stock Set to Benefit From the Launch of New BioInsight Division (Zacks)
08:21AM	ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves (Zacks)
Sep-29-25 08:30AM	CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO (GlobeNewswire)
Sep-26-25 10:05AM	CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program (Zacks)
Sep-25-25 11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 11:06AM	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-22-25 12:03PM	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU (Zacks)
11:29AM	FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing (Zacks)
Sep-18-25 10:54AM	Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification? (Zacks) +5.13%
09:17AM	Biogen Gets EU Nod for First Postpartum Depression Drug (Zacks)
Sep-17-25 02:27PM	Citizens JMP Reiterates a Buy Rating on CorMedix Inc. (CRMD) (Insider Monkey)
09:38AM	INCY Announces New Late-Stage Data on Skin Disease Drug (Zacks)
Sep-15-25 12:42PM	PBYI Surges 30% in 3 Months: How Should You Play the Stock? (Zacks)
10:27AM	CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? (Zacks)
09:52AM	Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain (Zacks)
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
09:55AM	CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Sep-08-25 08:30AM	Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market (PR Newswire)
08:30AM	CorMedix Announces Strategic Minority Investment in Talphera (GlobeNewswire)
Sep-04-25 02:56PM	Institutional Confidence Rises as CorMedix Inc. (CRMD) Hits Profitability (Insider Monkey) -6.57%
11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 10:02AM	Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results (Zacks) -6.42%
09:55AM	Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet (Zacks)
09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 10:18AM	Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path? (Zacks)
07:30AM	CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team (GlobeNewswire)
Sep-01-25 10:50AM	ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win (Zacks)
10:31AM	Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi (Zacks)
Aug-29-25 11:13AM	J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure (Zacks)
10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks)
05:05AM	CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio (Insider Monkey)
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dillione Janet	Director	Dec 02 '25	Option Exercise	3.96	46,657	184,802	95,130	Dec 04 09:30 PM
Dillione Janet	Director	Dec 02 '25	Sale	10.00	46,657	466,570	48,473	Dec 04 09:30 PM
Dillione Janet	Director	Nov 24 '25	Option Exercise	3.64	26,343	95,948	74,816	Nov 26 09:30 PM
Dillione Janet	Director	Nov 24 '25	Sale	9.93	26,343	261,586	48,473	Nov 26 09:30 PM
Janet Dillione	Director	Nov 24 '25	Proposed Sale	9.97	73,000	727,927		Nov 24 04:14 PM
Dillione Janet	Director	Nov 14 '25	Sale	11.42	30,000	342,600	48,473	Nov 18 09:45 PM
Dillione Janet	Director	Nov 14 '25	Proposed Sale	10.94	30,000	328,200		Nov 14 12:54 PM
Erin Mistry	Former Officer	Nov 10 '25	Proposed Sale	10.98	13,543	148,719		Nov 10 05:10 PM
Erin Mistry	Former Officer	Nov 06 '25	Proposed Sale	10.97	13,908	152,503		Nov 06 04:27 PM
Kaplan Myron	Director	Oct 23 '25	Buy	11.02	25,000	275,500	201,034	Oct 27 09:30 PM
Duncan Gregory Scott	Director	Sep 16 '25	Option Exercise	8.32	13,333	110,931	38,333	Sep 18 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Option Exercise	3.55	10,000	35,500	50,250	Sep 16 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Sale	13.13	10,000	131,300	40,250	Sep 16 09:45 PM
Todisco Joseph	Chief Executive Officer	Sep 12 '25	Option Exercise	3.47	50,000	173,500	559,496	Sep 12 09:45 PM
Todisco Joseph	Chief Executive Officer	Sep 12 '25	Sale	13.00	50,000	650,000	509,496	Sep 12 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Proposed Sale	13.10	10,000	130,950		Sep 12 04:37 PM
Todisco Joseph	Officer	Sep 12 '25	Proposed Sale	12.97	50,000	648,569		Sep 12 04:31 PM
Zelnick Kaufman Beth	Chief Legal Officer	Sep 09 '25	Option Exercise	3.30	50,000	165,000	230,418	Sep 11 09:45 PM
Zelnick Kaufman Beth	Chief Legal Officer	Sep 09 '25	Sale	13.41	50,000	670,264	180,418	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 11 '25	Option Exercise	1.45	41,121	59,625	218,111	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 09 '25	Option Exercise	1.45	12,876	18,670	189,866	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 11 '25	Sale	13.08	41,121	537,863	176,990	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 09 '25	Sale	13.51	12,876	173,955	176,990	Sep 11 09:45 PM
Zelnick Kaufman Beth	Officer	Sep 09 '25	Proposed Sale	13.46	50,000	673,000		Sep 09 04:52 PM
Hurlburt Elizabeth	Officer	Sep 09 '25	Proposed Sale	13.50	53,997	728,959		Sep 09 04:51 PM
David Matthew T	Former Officer	Sep 03 '25	Proposed Sale	14.50	300,000	4,350,000		Sep 03 04:32 PM
Lefkowitz Steven W	Director	Apr 02 '25	Option Exercise	4.03	20,000	80,600	120,498	Apr 03 04:30 PM
Todisco Joseph	Chief Executive Officer	Apr 01 '25	Option Exercise	3.38	59,170	199,995	530,721	Apr 02 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRMD

CorMedix Inc

Upgrade your FINVIZ experience